A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 6, 2014, Pages 619-627

  Gagne, Joshua J ^a   Wang, Shirley V ^a   Rassen, Jeremy A ^a   Schneeweiss, Sebastian ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Active; Distributed database; Monitoring; Pharmacoepidemiology; Prospective; Surveillance

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; AZITHROMYCIN; CELECOXIB; CERIVASTATIN; CIPROFLOXACIN; LISINOPRIL; MACROLIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; ROFECOXIB; ROSUVASTATIN; TELITHROMYCIN; TRICYCLIC ANTIDEPRESSANT AGENT; PRESCRIPTION DRUG;

ACHILLES TENDON RUPTURE; ANGIONEUROTIC EDEMA; ARTICLE; DIABETES MELLITUS; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ELECTRONIC MEDICAL RECORD; GASTROINTESTINAL HEMORRHAGE; HAZARD RATIO; HEART INFARCTION; HUMAN; LIVER TOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHABDOMYOLYSIS; AUTOMATION; DRUG MONITORING; FACTUAL DATABASE; POSTMARKETING SURVEILLANCE; PROCEDURES; RETROSPECTIVE STUDY; STANDARDS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AUTOMATION; DATABASES, FACTUAL; DRUG MONITORING; HUMANS; PRESCRIPTION DRUGS; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 84901812175     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3616     Document Type: Article

References (41)

1. Qureshi ZP, Seoane-Vazquez E, Rodriguez-Monguio R, Stevenson KB, Szeinbach SL. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol Drug Saf 2011; 20: 772-772.
2. Topol EJ. Failing the public health--rofecoxib, Merck, and the FDA. N Engl J Med 2004; 351: 1707-1709.
3. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633-1644.
4. Brown JS, Kulldorff M, Chan KA, et al. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol Drug Saf 2007; 16: 1275-1284.
5. Gagne JJ. You can observe a lot (about medical products) by watching (those who use them). Epidemiology 2013; 24: 700-702.
6. Trifiro G, Pariente A, Coloma PM, et al. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf 2009; 18: 1176-1184.
7. Platt R, Carnahan RM, Brown JS, et al. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf 2012; 21(Suppl 1): 1-8.
8. Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med 2010; 153: 600-606.
9. Toh S, Baker MA, Brown JS, Kornegay C, Platt R, Mini-Sentinel I. Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-Sentinel program. JAMA Intern Med 2013; 173: 817-819.
10. Observational Medical Outcomes Partnership: OMOP Web RL. 2013. [Accessed on February 22, 2014] at http://omop.fnih.org/.
11. Gagne JJ, Glynn RJ, Rassen JA, et al. Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system. Clin pharmacol Therapeut 2012; 92: 80-86.
12. Gagne JJ, Rassen JA, Walker AM, Glynn RJ, Schneeweiss S. Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. Epidemiology 2012; 23: 238-246.
13. Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA. Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther 2011; 90: 777-790.
14. Wahl PM, Gagne JJ, Wasser TE, et al. Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples. Drug Saf 2012; 35: 407-416.
15. Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 2010; 19: 858-868.
16. Gagne JJ, Fireman B, Ryan PB, et al. Design considerations in an active medical product safety monitoring system. Pharmacoepidemiol Drug Saf 2012; 21(Suppl 1): 32-40.
17. Taxonomy for monitoring methods within a medical product safety surveillance system: report of the Mini-Sentinel Taxonomy Project Work Group. 2010. Available at http://www.mini-sentinel.org/work_products/Statistical_Methods/Mini-Sentinel_FinalTaxonomyReport.pdf [9 September 2013].
18. Taxonomy for monitoring methods within a medical product safety surveillance system: year two report of the Mini-Sentinel Taxonomy Project Workgroup. 2012. Available at http://www.mini-sentinel.org/work_products/Statistical_Methods/Mini-Sentinel_Methods_Taxonomy-Year-2-Report.pdf [9 September 2013].
19. Gagne JJ, Glynn RJ, Rassen JA, et al. Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system. Clin Pharmacol Ther 2012; 92: 80-86.
20. Rassen JA, Avorn J, Schneeweiss S. Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases. Pharmacoepidemiol Drug Saf 2010; 19: 848-857.
21. Rassen JA, Glynn RJ, Brookhart MA, Schneeweiss S. Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol 2011; 173: 1404-1413.
22. Rassen JA, Solomon DH, Curtis JR, Herrinton L, Schneeweiss S. Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics. Med Care 2010; 48: S83-S89.
23. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009; 20: 512-522.
24. Curtis LH, Weiner MG, Boudreau DM, et al. Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf 2012; 21(Suppl 1): 23-31.
25. Modular Program 3: frequency of select events during exposure to a drug/procedure group of interest. 2013. Available at http://www.mini-sentinel.org/work_products/Data_Activities/Mini-Sentinel-Modular_Program_3-Documentation.pdf'
26. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol 2011; 64: 749-759.
27. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154: 854-864.
28. Rassen JA, Schneeweiss S. Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. Pharmacoepidemiol Drug Saf 2012; 21(Suppl 1): 41-49.
29. Gagne JJ, Wang S, Rassen JA, Glynn RJ, Schneeweiss S. Propensity scores in sequential monitoring of new drugs: evaluation of dynamic matching. Pharmacoepidemiol Drug Saf 2012; 21: 328.
30. Evaluating strategies for data sharing and analyses in distributed data settings. 2012. Available at http://www.mini-sentinel.org/work_products/Statistical_Methods/Mini-Sentinel_Methods_Evaluating-Strategies-for-Data-Sharing-and-Analyses.pdf [9 September 2013].
31. Rassen JA, Glynn RJ, Rothman KJ, Setoguchi S, Schneeweiss S. Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. Pharmacoepidemiol Drug Saf 2012; 21: 697-709.
32. Kulldorff M, Davis RL, Kolczak M, Lewis E, Lieu T, Platt R. A maximized sequential probability ratio test for drug and vaccin safety surveillance. Seq Anal 2011; 3: 58-78.
33. Gagne JJ, Bykov K, Willke RJ, Kahler KH, Subedi P, Schneeweiss S. Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research. Value Health 2013; 16: 1054-1062.
34. Gagne JJ, Walker AM, Glynn RJ, Rassen JA, Schneeweiss S. An event-based approach for comparing the performance of methods for prospective medical product monitoring. Pharmacoepidemiol Drug Saf 2012; 21: 631-639.
35. Solomon DH, Avorn J, Sturmer T, Glynn RJ, Mogun H, Schneeweiss S. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum 2006; 54: 1378-1389.
36. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109: 2068-2073.
37. Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med 2012; 172: 1582-1589.
38. Seeger JD, West WA, Fife D, Noel GJ, Johnson LN, Walker AM. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. Pharmacoepidemiol Drug Saf 2006; 15: 784-792.
39. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585-2590.
40. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 475-481.
41. Glynn RJ, Gagne JJ, Schneeweiss S. Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiol Drug Saf 2012; 21(Suppl 2): 138-147.